Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
Esther A ZaalWei WuGerrit JansenSonja ZweegmanJacqueline CloosCelia R BerkersPublished in: Cancer & metabolism (2017)
Our findings indicate that interfering with serine metabolism may be a novel strategy to improve bortezomib therapy and identify PHGDH as a potential biomarker for BTZ resistance.